End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 NZD | -6.25% |
|
-9.81% | -18.57% |
06-04 | New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio | MT |
06-03 | AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.57% | 183M | - | ||
+51.63% | 796B | C+ | ||
+41.51% | 628B | B | ||
-5.10% | 358B | C+ | ||
+19.90% | 331B | B- | ||
+9.95% | 301B | C+ | ||
+17.66% | 244B | B+ | ||
+3.39% | 228B | A+ | ||
+10.75% | 214B | B- | ||
+6.99% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFT Stock
- Ratings AFT Pharmaceuticals Limited